Skip to main content
Journal cover image

Application of mutagen sensitivity assay in a glioma case-control study.

Publication ,  Journal Article
Erdal, S; McCarthy, BJ; Gurule, N; Berwick, M; Gonzales, E; Byrd, J; Flores, K; Shimek, J; Il'yasova, D; Ali-Osman, F; Bigner, DD; Davis, FG ...
Published in: Toxicol Rep
2018

Few risk factors for glioma have been identified other than ionizing radiation. The alkylating agent acrylamide is a compound found in both occupational and the general environment and identified as one of the forty known or suspected neurocarcinogens in animal models. The mutagen sensitivity assay (MSA) has been used to indirectly show reduced DNA repair capacity upon exposure to ionizing radiation in those with glioma compared to controls. In this study, MSA was used to assess its applicability to a glioma case-control study and to test the hypothesis that subjects with glioma may have lower DNA repair capacity after exposure to selected potential human neurocarcinogens (i.e. acrylamide), compared to controls. Approximately 50 case and 50 control subjects were identified from a clinic-based study that investigated environmental risk factors for glioma, who completed an exposure survey, and had frozen immortalized lymphocytes available. A total of 50 metaphase spreads were read and reported for each participant. The association of case-control status with MSA for acrylamide, i.e. breaks per spread, was examined by multivariable logistic regression models. The mean number of breaks per slide was similar between hospital-based controls and cases. In addition, case-control status or exposure categories were not associated with the number of breaks per spread. Although the MSA has been shown as a useful molecular epidemiology tool for identifying individuals at higher risk for cancer, our data do not support the hypothesis that glioma patients have reduced DNA repair capacity in response to exposure to acrylamide. Further research is needed before the MSA is utilized in large-scale epidemiological investigations of alkylating agents.

Duke Scholars

Published In

Toxicol Rep

DOI

EISSN

2214-7500

Publication Date

2018

Volume

5

Start / End Page

183 / 188

Location

Ireland

Related Subject Headings

  • 4102 Ecological applications
  • 3214 Pharmacology and pharmaceutical sciences
  • 3206 Medical biotechnology
  • 1103 Clinical Sciences
  • 0399 Other Chemical Sciences
  • 0304 Medicinal and Biomolecular Chemistry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Erdal, S., McCarthy, B. J., Gurule, N., Berwick, M., Gonzales, E., Byrd, J., … White, K. A. M. (2018). Application of mutagen sensitivity assay in a glioma case-control study. Toxicol Rep, 5, 183–188. https://doi.org/10.1016/j.toxrep.2017.12.010
Erdal, Serap, Bridget J. McCarthy, Natalia Gurule, Marianne Berwick, Emily Gonzales, Johanna Byrd, Kristina Flores, et al. “Application of mutagen sensitivity assay in a glioma case-control study.Toxicol Rep 5 (2018): 183–88. https://doi.org/10.1016/j.toxrep.2017.12.010.
Erdal S, McCarthy BJ, Gurule N, Berwick M, Gonzales E, Byrd J, et al. Application of mutagen sensitivity assay in a glioma case-control study. Toxicol Rep. 2018;5:183–8.
Erdal, Serap, et al. “Application of mutagen sensitivity assay in a glioma case-control study.Toxicol Rep, vol. 5, 2018, pp. 183–88. Pubmed, doi:10.1016/j.toxrep.2017.12.010.
Erdal S, McCarthy BJ, Gurule N, Berwick M, Gonzales E, Byrd J, Flores K, Shimek J, Il’yasova D, Ali-Osman F, Bigner DD, Davis FG, Leyba AN, White KAM. Application of mutagen sensitivity assay in a glioma case-control study. Toxicol Rep. 2018;5:183–188.
Journal cover image

Published In

Toxicol Rep

DOI

EISSN

2214-7500

Publication Date

2018

Volume

5

Start / End Page

183 / 188

Location

Ireland

Related Subject Headings

  • 4102 Ecological applications
  • 3214 Pharmacology and pharmaceutical sciences
  • 3206 Medical biotechnology
  • 1103 Clinical Sciences
  • 0399 Other Chemical Sciences
  • 0304 Medicinal and Biomolecular Chemistry